Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Rhythm Biosciences Ltd. ( (AU:RHY) ) is now available.
Rhythm Biosciences Ltd announced a successful capital raising of up to $3.75 million through a share placement at $0.09 per share, supported by both existing and new investors. The funds will be used to launch the ColoSTAT® colorectal cancer test, accelerate the commercialisation of the geneType™ portfolio, and support further R&D activities. This strategic move is expected to enhance the company’s market position and operational capabilities in the cancer diagnostics industry.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is a transformative, predictive cancer diagnostics technology company focused on developing and commercializing diagnostic tests for cancer. Their primary products include the ColoSTAT® Multiplex diagnostic colorectal cancer test and the geneType™ cancer risk assessment product portfolio.
Average Trading Volume: 658,000
Technical Sentiment Signal: Buy
Current Market Cap: A$30.54M
For detailed information about RHY stock, go to TipRanks’ Stock Analysis page.